# US 2016/0354337 A1 · Melatonin agonist treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354337 A1
- Document ID: US20160354337A1
- Status: Published application
- Kind: A1
- Application number: 15/241,178
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2006-05-22
- Assignees: Vanda Pharmaceuticals Inc.
- Applicants: Vanda Pharmaceuticals, Inc.
- Inventors: Gunther Birznieks; Deepak Phadke; Mihael H. Polymeropoulos
- Web page: https://patentgrep.com/patent/US20160354337A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61P 5/04: for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Melatonin Agonist, MA-1, is administered at effective doses.

## Claims

### Claim 1

A method for forward shifting melatonin onset in a human subject experiencing a 5 hour circadian phase advance, said method comprising orally administering to the subject 20 mg/d (1R-trans)-N-r-(2,3-dihydro-4-benzofuranyl)cyclopropyllmethyllpropanamide (MA-1) in immediate release form at or within 2 hours prior to the subject's phase-advanced bedtime.

### Claim 2 (depends on 1)

The method of claim 1 for forward shifting melatonin onset in the human subject by at least about one hour on the first day of treatment.

### Claim 3 (depends on 1)

The method of claim 1, wherein the MA-1 is administered within about 0.5 hour prior to bedtime.

### Claim 4 (depends on 2)

The method of claim 2, wherein the MA-1 is administered within about 0.5 hour prior to bedtime.

### Claim 5

A method of treating a circadian rhythm disorder associated with a 5-hour circadian phase advance in a human subject, said method comprising forward shifting the circadian sleep-wake cycle in the subject by orally administering to the subject 20 mg/d (1R-trans)-N-r-(2,3-dihydro-4-benzofuranyl)cyclopropyllmethyll propanamide (MA-1) in immediate release form at or within 2 hours prior to the subject's phase-advanced bedtime.

### Claim 6 (depends on 5)

The method of claim 5 of treating the circadian rhythm disorder by forward shifting the circadian sleep-wake cycle in the subject by at least about one hour on the first day following the phase advance by orally administering to the subject 20 mg/d (1R-trans)-N-N-(2,3-dihydro-4-benzofuranyl)cyclopropyllmethyll propanamide (MA-1) in immediate release form at or within 2 hours prior to the subject's phase-advanced bedtime.

### Claim 7 (depends on 5)

The method of claim 5, wherein the MA-1 is administered within about 0.5 hour prior to bedtime.

### Claim 8 (depends on 6)

The method of claim 6, wherein the MA-1 is administered within about 0.5 hour prior to bedtime.
